Dynacare, Intema Join Forces to Offer Advanced Prenatal Testing

Expectant Mothers Now Have a Safer, More Accurate

Screening Option for Detecting Birth Defects



Apr 16, 2001, 01:00 ET from Dynacare Inc.

    DALLAS, TX and OXFORD, UK, April 16 /PRNewswire/ - Dynacare Inc. (Nasdaq:  
 DNCR; TSE: DNA) and Intema Ltd. announced today that they have signed an
 agreement to develop and implement an advanced integrated prenatal testing
 system.
     This breakthrough technology provides higher detection rates for Down
 syndrome than screening tests currently available and greatly reduces the need
 for expectant mothers to undergo amniocentesis, which can increase the risk of
 miscarriage.
     Dynacare, through Dynagene, its center for genetic testing and
 counseling, is the first clinical laboratory in the United States to offer
 this new integrated prenatal test.
     With more women delaying motherhood and thus increasing their risk of
 pregnancy complications, the demand for more effective prenatal screening is
 greater than ever before. With access to Intema's methodologies, Dynacare is
 meeting that demand by offering its "Integrated Prenatal Risk Profile." This
 unique approach allows for the detection of an unparalleled 85 percent of Down
 syndrome pregnancies with a false positive rate of only 1 percent, thus
 leading to fewer procedure-related pregnancy losses. This is compared to the
 traditional testing method called "the triple screen," that typically has a
 false positive rate of about 5 percent.
     "Through our relationship with Intema, Dynacare is taking the lead in
 providing expectant mothers with a better option in determining their risk of
 having a child with Down syndrome," says Harvey Shapiro, president and CEO of
 Dynacare. "This new integrated prenatal testing service is consistent with our
 mission to provide our physician clients and their patients with superior
 testing capabilities that yield accurate and timely results."
     Each year approximately 60 percent, or 2.4 million pregnant women in the
 United States undergo prenatal screening for birth defects. Women who screen
 positive are usually referred for amniocentesis, which is costly and carries
 about a 1 percent risk of a procedure-related miscarriage, according to
 academic literature. If these women opt for the new Integrated Prenatal Risk
 Profile, more than 80 percent of amniocentesis procedures would be avoided.
     The Integrated Prenatal Risk Profile combines information from
 biochemical markers obtained through blood analysis in the first and second
 trimester with a measurement made via ultrasonography taken in the first
 trimester. This information is used to arrive at a single estimate of risk
 that incorporates all information about the fetus available through non-
 invasive techniques. The result is a better risk estimate for Down syndrome.
     Professor Nicholas Wald, developer of the integrated test and founder of
 Intema, says "the integrated test - followed by diagnostic amniocentesis for
 those who screen positive - is the most effective and safe method of detecting
 Down syndrome in early pregnancy."
     Wald is an epidemiologist, internationally recognized for his
 contributions to prenatal screening and birth defect prevention. His findings
 were published in The New England Journal of Medicine in August 1999. Wald is
 also credited for being the first to show conclusively that folic acid reduces
 birth defects.
     "I am pleased that Dynacare is taking this initiative," he adds.
 "Dynacare has the facilities, the expertise, the vision and the enthusiasm to
 improve the standard of care in prenatal screening. We share a common purpose
 to provide women with better and safer screening services."
     For more information about the Integrated Prenatal Risk Profile, please
 call Dynacare/Dynagene client services at 1-800-458-6836 and ask for extension
 6008.
 
     About Dynacare and Dynagene
 
     Dynacare's expertise in target regional markets and hospital partnerships
 allow the company to provide innovative and trusted clinical laboratory
 services to its clients, their patients and professional partners. Dynacare
 operates in 20 U.S. states with a significant presence in Canada. Dynacare's
 laboratory partners include: Memorial Hermann Healthcare System in Houston,
 TX, University Health System, Inc. in Knoxville, TN (Owner/Operator of the
 University of Tennessee Medical Center), Froedtert Memorial Lutheran Hospital
 in Milwaukee, WI, and Allegheny General Hospital, a member of the West Penn
 Allegheny Health System in Pittsburgh, PA. Further information about Dynacare
 can be obtained from the company's website at www.dynacare.com.
     Launched in November of 2000, Dynagene, Dynacare's Center of Excellence
 for Genetic Testing and Counseling, performs genetic reference work for all
 Dynacare laboratories, as well as referring physicians, and independent
 laboratories throughout North America. Dynagene provides a full range of
 genetic services including prenatal, postnatal, and cancer cytogenetics, FISH
 testing, molecular genetics, and genetic counseling. Further information on
 Dynagene can be found on the company's website at www.dynagene.com.
 
     About Intema, Ltd.
 
     Intema, Ltd. was founded in 2000 by Professor Nicholas Wald to license
 the integrated test, and provide associated quality assurance and educational
 support.
 
     This press release may contain "forward-looking statements" within the
 meaning of Section 21E of the Securities Exchange Act of 1934. When used in
 this press release, the words "may," "could," "should," "would," "believe,"
 "anticipate," "estimate," "expect," "intend," "plan" and similar expressions
 or statements regarding future periods are intended to identify forward-
 looking statements. All forward-looking statements are inherently uncertain as
 they are based on various expectations and assumptions concerning future
 events, which by their nature involve substantial risks and uncertainties
 beyond Dynacare Inc.'s control. Dynacare Inc. undertakes no obligation to
 update or revise any forward-looking statement for events or circumstances
 after the date on which such statement is made. Dynacare Inc. cannot assess
 the impact of or the extent to which any single factor or risk, or combination
 of them, may cause actual results to differ materially from those contained in
 any forward-looking statements. For a more complete discussion of risk
 factors, please see Dynacare Inc.'s filings with the Securities and Exchange
 Commission, including its Registration Statement on Form F-1 filed on
 September 29, 2000 and subsequently amended and its Annual Report on Form 10-K
 for the year ended December 31, 2000.
 
 

SOURCE Dynacare Inc.
    DALLAS, TX and OXFORD, UK, April 16 /PRNewswire/ - Dynacare Inc. (Nasdaq:  
 DNCR; TSE: DNA) and Intema Ltd. announced today that they have signed an
 agreement to develop and implement an advanced integrated prenatal testing
 system.
     This breakthrough technology provides higher detection rates for Down
 syndrome than screening tests currently available and greatly reduces the need
 for expectant mothers to undergo amniocentesis, which can increase the risk of
 miscarriage.
     Dynacare, through Dynagene, its center for genetic testing and
 counseling, is the first clinical laboratory in the United States to offer
 this new integrated prenatal test.
     With more women delaying motherhood and thus increasing their risk of
 pregnancy complications, the demand for more effective prenatal screening is
 greater than ever before. With access to Intema's methodologies, Dynacare is
 meeting that demand by offering its "Integrated Prenatal Risk Profile." This
 unique approach allows for the detection of an unparalleled 85 percent of Down
 syndrome pregnancies with a false positive rate of only 1 percent, thus
 leading to fewer procedure-related pregnancy losses. This is compared to the
 traditional testing method called "the triple screen," that typically has a
 false positive rate of about 5 percent.
     "Through our relationship with Intema, Dynacare is taking the lead in
 providing expectant mothers with a better option in determining their risk of
 having a child with Down syndrome," says Harvey Shapiro, president and CEO of
 Dynacare. "This new integrated prenatal testing service is consistent with our
 mission to provide our physician clients and their patients with superior
 testing capabilities that yield accurate and timely results."
     Each year approximately 60 percent, or 2.4 million pregnant women in the
 United States undergo prenatal screening for birth defects. Women who screen
 positive are usually referred for amniocentesis, which is costly and carries
 about a 1 percent risk of a procedure-related miscarriage, according to
 academic literature. If these women opt for the new Integrated Prenatal Risk
 Profile, more than 80 percent of amniocentesis procedures would be avoided.
     The Integrated Prenatal Risk Profile combines information from
 biochemical markers obtained through blood analysis in the first and second
 trimester with a measurement made via ultrasonography taken in the first
 trimester. This information is used to arrive at a single estimate of risk
 that incorporates all information about the fetus available through non-
 invasive techniques. The result is a better risk estimate for Down syndrome.
     Professor Nicholas Wald, developer of the integrated test and founder of
 Intema, says "the integrated test - followed by diagnostic amniocentesis for
 those who screen positive - is the most effective and safe method of detecting
 Down syndrome in early pregnancy."
     Wald is an epidemiologist, internationally recognized for his
 contributions to prenatal screening and birth defect prevention. His findings
 were published in The New England Journal of Medicine in August 1999. Wald is
 also credited for being the first to show conclusively that folic acid reduces
 birth defects.
     "I am pleased that Dynacare is taking this initiative," he adds.
 "Dynacare has the facilities, the expertise, the vision and the enthusiasm to
 improve the standard of care in prenatal screening. We share a common purpose
 to provide women with better and safer screening services."
     For more information about the Integrated Prenatal Risk Profile, please
 call Dynacare/Dynagene client services at 1-800-458-6836 and ask for extension
 6008.
 
     About Dynacare and Dynagene
 
     Dynacare's expertise in target regional markets and hospital partnerships
 allow the company to provide innovative and trusted clinical laboratory
 services to its clients, their patients and professional partners. Dynacare
 operates in 20 U.S. states with a significant presence in Canada. Dynacare's
 laboratory partners include: Memorial Hermann Healthcare System in Houston,
 TX, University Health System, Inc. in Knoxville, TN (Owner/Operator of the
 University of Tennessee Medical Center), Froedtert Memorial Lutheran Hospital
 in Milwaukee, WI, and Allegheny General Hospital, a member of the West Penn
 Allegheny Health System in Pittsburgh, PA. Further information about Dynacare
 can be obtained from the company's website at www.dynacare.com.
     Launched in November of 2000, Dynagene, Dynacare's Center of Excellence
 for Genetic Testing and Counseling, performs genetic reference work for all
 Dynacare laboratories, as well as referring physicians, and independent
 laboratories throughout North America. Dynagene provides a full range of
 genetic services including prenatal, postnatal, and cancer cytogenetics, FISH
 testing, molecular genetics, and genetic counseling. Further information on
 Dynagene can be found on the company's website at www.dynagene.com.
 
     About Intema, Ltd.
 
     Intema, Ltd. was founded in 2000 by Professor Nicholas Wald to license
 the integrated test, and provide associated quality assurance and educational
 support.
 
     This press release may contain "forward-looking statements" within the
 meaning of Section 21E of the Securities Exchange Act of 1934. When used in
 this press release, the words "may," "could," "should," "would," "believe,"
 "anticipate," "estimate," "expect," "intend," "plan" and similar expressions
 or statements regarding future periods are intended to identify forward-
 looking statements. All forward-looking statements are inherently uncertain as
 they are based on various expectations and assumptions concerning future
 events, which by their nature involve substantial risks and uncertainties
 beyond Dynacare Inc.'s control. Dynacare Inc. undertakes no obligation to
 update or revise any forward-looking statement for events or circumstances
 after the date on which such statement is made. Dynacare Inc. cannot assess
 the impact of or the extent to which any single factor or risk, or combination
 of them, may cause actual results to differ materially from those contained in
 any forward-looking statements. For a more complete discussion of risk
 factors, please see Dynacare Inc.'s filings with the Securities and Exchange
 Commission, including its Registration Statement on Form F-1 filed on
 September 29, 2000 and subsequently amended and its Annual Report on Form 10-K
 for the year ended December 31, 2000.
 
 SOURCE Dynacare Inc.